Hey cancer.
You picked the
wrong fight.

Behold the revolution in endoscopic cancer diagnostics and treatment. Multi4 removes urinary bladder cancer in an effortless, automated and human-centric way. Cancer may have started the fight, but we’ll win the war. Together as one.

World-unique technology.

Multi4 is the first in the world to succeed in developing automated technology for endoscopic cancer diagnosis and treatment. The new and patented technology will be a game changer for millions of patients worldwide.

Multi4 is a statement that says
F@*# cancer.

Bladder cancer ranks as the sixth most common cancer worldwide. 1 650 000 prevalent cases, 550 000 new cases and almost 200 000 deaths annually in 2018. 75% of all bladder cancer cases occur in men. It has a high recurrence rate with an average of 61% in year one and 78% over five years. Bladder cancer is the 6th most prevalent cancer in both sexes worldwide, the 4th in men.

Removing suffering from the equation.

Multi4 is a groundbreaking and multiple award-winning innovation for cancer diagnostics and treatment, especially suited for urinary bladder cancer. It’s a game-changer for patients, families, hospitals, medical professionals and society as a whole. Not only can it remove cancer tissue, it can also significantly reduce costs. Above all, Multi4 is designed to reduce human suffering and improve quality of life.

Patented revolutionary technology.

World-unique newly developed technology makes it possible to use the Multi4 instrument in the small working channel of a endoscope! The technology is generic and can later be used for cancer of the esophagus, stomach, lungs and intestines. With several robust patent families, the new technologies are well protected on the world market.

Handheld and automated precision.

Multi4 is a powerful multipurpose instrument with 4 built-in functions. Apply local anesthesia, take tissue samples in a completely new way, automatically transport tissue samples through the instrument itself and destroy cancer tissue or stop bleedings with one single instrument. Multi4 is ergonomically designed with gender inclusion in mind. Regardless of your gender or handedness, the future is in the palm of your hand.

No need to do things the hard way.

Multi4 doesn’t require the patient to wait for treatment, no fasting, no spinal or general anesthesia, no sterile surgery preparations, no operating room,  and no catheter. When done with the treatment, the patient can go home, no need to stay in a hospital. Multi4 is developed to be used in outpatient care.

The game changer in endoscopic cancer diagnostics and treatment.

From inpatient care to outpatient care.

Awards

2019
Quality innovation Award Sweden
Award Ceremony Stockholm, Sweden, Feb 2020
2019
”Guldenen” Incubator company of the year
Science Park Jönköping, Award Ceremony in Feb 2020
2019
Innovation of the year
Almi & Science Park, Jönköping
2020
Quality innovation Award Worldwide
Award Ceremony Tel Aviv, Israel, Feb 2020
2020
Entrepreneur scholarship
The Knut & Ragnvi Jacobsson Family Foundation
2021
Entrepreneur prize
The Knut and Ragnvi Jacobsson family foundation
2021
Entrepreneur Prize
Fontana
2021
Innission Innovation Award
Inission
2022
The Startup Company of the year in the Nordics
Techarenan
2022
Top 2 Start-up in the Nordics
She loves Tech
2022
The Innovator of the year
Nordic Woman in Tech
2022
Superstar
Addher Awards
2022
Jönköping resident of the month
Jönköpingsposten
2023
Nordic Amplify- accelerated US market entry
Business Sweden/Nordics-Greater Winston Salem/

Timeline

2021
Preclinical study in animals

Performed in collaboration with RISE-research institute in Sweden, the University of Gothenburg Sweden and The Urology Clinic at Sahlgrenska University Hospital in Sweden.

2023
Clinical trial

Regulatory and Quality

CE-Mark & FDA

Work is being done to meet both

MDR & FDA requirements.

Launch

Multi4 on the market

Comparison

Multi4
Resectoscope
Complete treatment time for physician (min)
5-30
20-60
Complete time for the patient at hospital (hours)
0,5-1
6-48
People needed for the treatment
1(2)
6-16
Urethra catheter needed
No
Yes
Spinal or general anesthesia
No
Yes
Cancer treatment is performed directly at the same visit as the control cystoscopy
Yes
No
Cancer treatment performed in outpatient care
Yes
No
Full sterility is required to perform the treatment
No
Yes
Fasting
No
Yes
Training time to learn to perform the surgery
2-10 Hours
Years of training
Waiting time to treatment
No
Yes
Automatic transport of cancerous tissue out of body
Yes
No
Automatic collection of all tissue samples in a container ready to send to the pathologist
Yes
No
The instrument needs to be brought in and out several times manually
No
Yes

Market

Shape the future in 30 minutes

Traditional bladder cancer diagnostics and treatment methods are expensive. Urinary bladder cancer has the highest per patient lifetime treatment costs of any cancer. The paper ”Economic Burden of Bladder Cancer Across the European Union” estimates that bladder cancer cost EU €4.9 billion in 2012. This amounted to 3 percent of all cancer costs.
It is estimated that upwards of $5.71 billion will be spent on bladder cancer in the US in the year 2020. The high cost shows the great need to improve the management of bladder cancer for the benefit of patients, healthcare systems and payers.

Today’s methods are both labor intensive and time consuming.
Multi4 cuts away many steps while adding value in the process.
Treatment is performed at the first visit in just 30 minutes in an outpatient setting.

The Multi4 instrument changes positions

There are many surgeries performed annually for bladder cancer, not least because the recurrence rate is so high. In the EU5 countries, 360,000 surgeries and in the United States, 315,000 are performed annually (transurethral resections of bladder cancer).

In addition, the world new Multi4-technology is scalable and can be used for cancer in other organs. The global market for endoscopes and associated equipment has an annual turnover of EUR 22,5 billion. Approximately 30% of this market. EUR 7 billion, consists of endoscopy accessories.

The market for diagnostic endoscopic biopsy instruments is expected to continue to grow from approximately EUR 1.5 billion in 2016 to approximately EUR 2.2 billion in 2022. Unfortunately, the number of cancer patients is increasing annually, new screening programs are introduced and the need for tissue sampling for diagnostics is increasing.

High quality partners

Multi4 collaborates with RISE – The research institute of Sweden.
RISE is a strong innovation partner who provides comprehensive support and a broad range of perspectives. RISE coordinates innovation research on Multi4 and assists with important regulatory expertise.

Join the fight against cancer

We work in parallel with many processes instead of serially to ensure a fast and high-quality journey towards launch so patients can get a treatment of their cancer without waiting times, in an easier way with less suffering , while healthcare and society save millions.

Don’t hesitate to contact us if you want to join our journey to fight cancer and reduce suffering for cancer patients around the world!

A broad and
committed team

We are many who fight cancer together. We work with passion and we have a higher purpose.
In addition to a very driven management team that works operationally with a team of engineers, there are many people involved in the work every day. We work closely with two different patent office’s specializing in Med Tech to ensure a robust IP-portfolio.
Always available and so incredibly important are all colleagues in the healthcare sector, doctors, nurses, endoscopists and assistant nurses, but also directors, managers and professors who are engaged on demand from the start and help us move forward. You are all worth gold.

Multiple Prize Winner.

Proudly Funded by Contributions from Sweden & the European Union.